APP and Alzheimer disease: In accordance with these results, our results confirm that the chronic administration of DXI reduces weight gain, glucose and insulin impaired response and insulin signaling pathway alterations in liver induced by HFD intake in APP/PS1 mice, reverting the metabolic alterations tightly associated to AD development.